Creatinine Test Market Research Report - Global Forecast till 2023
ID: MRFR/HC/3449-CRR | | Region: Global | 110 pages | Cooked Research Reports
Global Creatinine Test Market Research Report By Test Type (Blood Test, Urine Test and Creatinine Clearance Test), By Product Type (Consumables and Instruments), By Application (Urinary Tract Obstruction, Renal Failure, Kidney Cancer, Glomerulonephritis and Others), By End User (Hospital & Clinics, Diagnostic Center, Research Institutes and Others), By Region – Forecast to 2023
Market Description
The global creatinine test market is anticipated to reach USD 604.5 million by 2023, as per a new report by Market Research Future (MRFR). It is expected to exhibit a phenomenal CAGR during the assessment period (2017-2023). The growth is supplemented by government initiatives and campaigns to create awareness among users to minimize the incidence of chronic kidney diseases. In addition, launch of diagnostic tests annually by current and new manufacturers is anticipated to spur market growth over the forecast period.
Creatinine tests are an array of tests used in checking on creatinine levels in kidneys. Creatinine is a waste product filtered through the kidneys and excreted via urine. Excess of creatinine in the blood can lead to kidney failure. Tests such as creatinine clearance and others to discern the glomerular filtration rate (GFR) are expected to diagnose chronic kidney disease at an early stage. Automation of laboratory tests and rise in research and development to expedite testing rates are expected to augur the creatinine test market over the forecast period.
Unmet needs for efficient creatinine level diagnostic tests coupled with sedentary lifestyles globally are factors expected to drive market growth. Technological advances in these tests can detect improper functioning of the kidneys. The application of creatinine tests in emergency wards, outpatient clinics, and hospitals can provide new opportunities for the market.
Report Overview
This report allows the user to gain a deeper understanding of the ongoing events and trends in the global market for creatinine tests. By correlating the historical data with key market dynamics, analysts were able to make highly accurate projections in the report. MRFR’s report includes a thorough segmental analysis of the global creatinine test market segmented by test type, product type, application, end-user, and region with astute insights. This report has been prepared to assist industry participants in making informed decisions on growth strategies and operation management. Users will also come across drivers, trends, opportunities, and restraints which are likely to influence the growth of the market during the assessment period.
Segment Overview
By test type, the creatinine test market has been segmented into urine test, creatinine clearance test, and blood test. By product type, the market is segmented into consumables and instruments. Based on application, the market has been segmented into glomerulonephritis, kidney cancer, renal failure, urinary tract obstruction, and others. End-users covered are research institutes, diagnostic centers, hospitals & clinics, and others.
The segments and sub-segments covered in the report are analyzed under four major regions –Americas, Europe, Asia Pacific, and the Middle East and Africa, with respective country-level market sizing. For the scope of research, the standard definition of the product/ service “creatinine test” is included in the report. The report discusses and interprets the current and future opportunities of the industry delivering an unbiased growth assessment.
Players Covered
Quest Diagnostics, Thermo Fisher Scientific, Inc., Abbott, F. Hoffmann-La Roche AG, ARKRAY, Inc., ACON Laboratories, Inc., Abcam plc, URIT Medical, The Danaher Corporation, Siemens AG, Nova Biomedical, OPTI Medical Systems, and others are prominent players in the creatinine test market.
The report offers comprehensive profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, segmental share, SWOT analysis, growth strategies, new product launches, M&A activities, and latest R&D initiatives are outlined in the report.
Research Methodology
Market Research Future (MRFR) uses a combination of primary and secondary research to compile market reports. Primary data is accumulated from interviewing industry stalwarts and secondary research is collated by studying white papers and annual reports of leading players. Our analysts use top-down and bottom-up approaches to validate the findings of the report. The report consists of news, current trends, and future prospects related to the market, all of which can provide a thorough understanding of the market to clients. Industry leaders can make accurate business decisions based on our insights.
Analysis Period
- Base Year - 2016
- Projection Period - From 2017 to 2023
- Market Denomination - USD Million
- Conversion Rate - Considered as per the respective financial years
For the scope of the research, the report offers a comprehensive analysis of the global creatinine test market
Test Type
- Blood Test
- Blood Urea Nitrogen Test
- Serum Creatinine Test
- Estimated Glomerular Filtration (eGFR) Test
- Urine Test
- A:C Test
- P:C Test
- Creatinine Clearance Test
By Product Type
- Consumables
- Cartridge
- Urine Test Strips
- Others
- Instruments
- Clinical Analyzers
- Benchtop Clinical Analyzer
- Automated
- Semi-automated
- Handheld Clinical Analyzer
- Benchtop Clinical Analyzer
- Others
- Clinical Analyzers
Application
- Urinary Tract Obstruction
- Glomerulonephritis
- Kidney Cancer
- Renal Failure
- Others
End User
- Research Institutes
- Diagnostic Centers
- Hospitals & Clinics
- Others
By Region
- Americas; North America and South America,
- Europe; Western and Eastern Europe
- Asia Pacific (APAC); China, Japan, India, Australia, Republic of Korea, and Rest of Asia Pacific
- Middle East & Africa; The Middle East and Africa
Intended Audience
- Diagnostic Centers
- Research and Development (R&D) Companies
- Government Research Institutes
- Academic Institutes and Universities
Global Creatinine Test Market: Report Summary
The global creatinine test market is anticipated to reach a valuation of USD 604.55 million by 2023, expanding at a 5.8% CAGR during the assessment period (2018-2023). Alarming cases of kidney disorders, namely chronic kidney disease (CKD) among patients is expected to be the primary driver of the market. In addition, government initiatives by various nations to create awareness among patients can propel market demand in the coming years.
Creatinine tests are an array of tests used to discern creatinine levels in the blood. Creatinine is a waste product created during the breakdown of creatine, an organic acid found in vertebrates. Development of various tests such as blood urea nitrogen (BUN) test, estimated glomerular filtration rate (eGFR) test, and others can provide accurate results and assist in preventive healthcare. The rise in the geriatric populace and increasing cases of diabetics can purportedly drive the demand for creatinine tests over the forecast period.
The creatinine test market has been segmented by test type, product type, application, end-user, and region. By type, the market is segmented into blood test, creatinine clearance test, and urine test. The blood test segment is expected to generate market revenue owing to high preference of blood tests to measure creatinine levels. It was worth USD 211.83 million in 2016 and purportedly expand at a 5.32% CAGR during the forecast period. The urine test segment can grow robustly over the forecast period owing to advances in urine test strips to determine a rapid and accurate diagnosis of kidney disorders.
By product type, the market is segmented into consumables and instruments. The consumables segment is likely to register a remarkable growth rate during the forecast period owing to urine test strips and cartridges being used for rapid diagnosis of creatinine in the urine. The instruments segment is projected to grow at a brisk pace and exhibit a 6% CAGR during the forecast period.
On the basis of application, the market has been segmented into kidney cancer, renal failure, glomerulonephritis, urinary tract obstruction, and others. The urinary tract obstruction segment is expected to showcase a 5.10% CAGR over the forecast period owing to serum creatinine tests used to determine blockage of the urinary tract.
Major market end-users include research institutes, diagnostic centers, hospitals and clinics, and others. The diagnostic centers segment is projected to register a 6.34% CAGR during the forecast period owing to high demand for early diagnosis of CKD.
Regional Analysis
On the basis of regions, the global creatinine test market has been segmented into Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).
The Americas market accounted for a large market share owing to presence of various leaders of the healthcare industry, expanded healthcare budget, reimbursement policies, and prevalence of various kidney diseases. According to a 2017 report by the National Center for Chronic Disease and Prevention, nearly 30 million citizens in the U.S. were dealing with some form of kidney disorder. Inclination towards quality healthcare is expected to bode well for the market over the forecast period.
The Europe market is expected to exhibit a 6.12% CAGR from 2017 to 2023. Countries such as the U.K., France, and Germany are projected to contribute to market demand owing to change in healthcare policies.
The APAC market is deemed to grow at a rapid pace during the forecast period owing to a large patient pool, improving healthcare infrastructure, and changing healthcare models of hospitals. It is expected to exhibit a 6.33% CAGR from 2017 to 2023 owing to helpful government initiatives to create awareness and subsidies offered to hospitals for implementation of rapid diagnostic tests.
Competitive Analysis
Siemens AG, Abcam plc, ACON Laboratories, Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., Quest Diagnostics, URIT Medical, The Danaher Corporation, Abbott Diagnostics Inc., Nova Biomedical, OPTI Medical Systems, ARKRAY, Inc., and others are some of the noteworthy players in the creatinine test market. Acquisitions and new product launches are strategies employed by players to gain a larger share in the market. Development of new standards by regulatory agencies to ease the approval process of new product launches is expected to open up new growth opportunities for the market. For instance, BUN and total carbon dioxide (TCO2) point-of-care tests by Siemens Healthcare were approved in 2018 by the U.S. Food and Drug Administration (FDA) to assist in the diagnosis of renal diseases.
TABLE OF CONTENTS
Global Creatinine Test Market: Competitive Landscape
Siemens AG, Abbott Diagnostics Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche AG, and The Danaher Corporation collectively accounted for more than 70.5% market share of the global creatinine test market in 2016. These companies continue to retain their strong global presence through acquisitions and product launches.
In 2016, Siemens accounted for the largest market share of the global creatinine test market, with more than 21.2% of the market share. The large share of the company is attributed to the high demand for creatinine testing globally. Moreover, this company offers various new products in the creatinine test market. For instance, in 2018, Siemens Healthineers received an FDA approval for its Blood Urea Nitrogen (BUN) and Total Carbon Dioxide (TCO2) point-of-care tests to aid in the diagnosis of renal diseases and metabolic imbalances.
Abbott held the second position in terms of market share, in 2016. The company focuses on delivering integrated solutions to large healthcare customers. Also, the company is focusing on acquisitions for establishing a strong position in the market. For instance, in Oct 2017, Abbott completed the acquisition of Alere Inc. for USD 5.3 Billion. The acquisition will establish a strong position of Abbott in the diagnostics market.
Thermo Fisher Scientific Inc. acquired the third spot in the market. The company follows a strategy of introducing a strong product portfolio at lower costs which help them to retain the position in the market.
- Hoffmann-La Roche AG holds the fourth place in the market owing to the strategy of identifying & developing promising technologies and potential products and focusing on merging and acquisitions with other groups to develop and identify new products and technologies. For instance, in Nov 2017, Roche announced to acquire Viewics, Inc. to expand its leading position in the Integrated Core Lab with business analytics capabilities.
The Danaher Corporation is a global technology and science innovator focusing on helping their customers solve complex challenges and improve quality of life around the world. It holds the fifth position in the global creatinine test market owing to new launches and global presence in the market. In 2017, the company announced the launch of its CE-marked point-of-care tests for creatinine and urea, the latest additions to the ABL90 FLEX PLUS blood gas analyzer’s test menu.
There are many other players present in the market such as ARKRAY, Inc., Quest Diagnostics Inc., URIT Medical, OPTI Medical Systems, Inc., ACON Laboratories, Inc., Nova Biomedical, Abcam plc, and others which accounts cumulatively for nearly 29.5% of the global market share. The companies are adopting the strategy of product launches and acquisitions to solidify their position in the market. New product developments are a key focus area for players.
